November 17, 2025

ADA seeks feedback on oral cancer recommendations

The ADA Living Guideline Program is continuing its work to advance recommendations for the early detection and management of oral cancer.

ADA News

November 13, 2025

Swallowing Safely: Evidence-Based Approaches to Tablets and Dysphagia

In stroke patients with dysphagia, the default practice of crushing tablets could increase residue, reduce efficacy, and raise aspiration risk. Researchers reveal how individualized FEES assessments can transform medication safety at the bedside.

The Medicine Maker

November 12, 2025

Florida Combined Life drops policy limiting same-day scaling and root planing following ADA advocacy

Florida Combined Life is dropping its policy that limited same-day scaling and root planing to only two quadrants.

ADA News

November 10, 2025

Offering Ocular Aesthetics

The demand for noninvasive aesthetic treatments, such as skin rejuvenation, is on the rise in the United States. Specifically, the market size was estimated to be $20.8 billion in 2023, and it is expected to increase at a compound annual growth rate of 14.1% to 2030, according to Grand View Research.

Optometric Management

November 10, 2025

Coding: Closing the Year Strong

By carefully analyzing and cleaning up your AR before January, you can set the stage for a stronger financial performance in 2026. Here's how...

Optometric Management

November 10, 2025

Long-Term Safety and Management of Adverse Events Associated With Lorlatinib in ALK-Positive Metastatic NSCLC: A Fictional Case Study

Explore how lorlatinib transformed treatment outcomes for a patient with ALK-positive metastatic NSCLC while highlighting the importance of effective management strategies.

JADPRO

November 10, 2025

FDA Approves Epioxa for Keratoconus

Glaukos’ Epioxa is the first incision-free drug therapy for the condition

The Ophthalmologist

November 10, 2025

HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings

Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative se...

The ASCO Post

November 10, 2025

Alcohol and Cancer Risk: Is a Drop Too Much?

In 2022, Congress requested a scientific review from the National Academies of Sciences, Engineering, and Medicine (NASEM) to study the associated risks of cancer and other health conditions and the u...

The ASCO Post